Tirzepatide Research

Qiao Y, Zhou F, Mao T, Gao L

Glucose-dependent insulinotropic polypeptide (GIP), once the overlooked sibling of the incretin family, is now experiencing a research renaissance. Historically, its therapeutic development was hindered by a seemingly diminished insulinotropic effect in type 2 diabetes (T2DM), its paradoxical sti...

Chen Q, Chen T, Lin W, Chen X

To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formulary selection.This study was structured according to the "A...

Mehta S, Gillani SF, Elkomi R, Michael M

Schaefer LM, Kerver GA, Allison KC, Kohoutek B, Steffen KJ

Limited available data indicate that glucagon-like peptide-1 (GLP-1) medications may significantly reduce weight and binge-eating symptoms among patients with binge-eating disorder. However, experts express concern about the potential for GLP-1 medications to cause unintended harm or be misused a...

Smith BL, May A, Lalani F, Hasham S, Presnell AA

Obesity is a chronic, multifactorial disease associated with significant metabolic, physical, and psychosocial complications. Although advances in pharmacologic therapy-particularly glucagon-like peptide-1 (GLP-1)-based agents-have expanded treatment options, challenges persist in the effective m...

Herrera HO, Bordeaux JS

Corrêa LMA, Mazur GR, Santiago CBG, Dante LE, de Marco PS, Ferrés PBS et al.

Post-transplant metabolic management remains challenging, as immunosuppression exacerbates diabetes and obesity, threatening graft outcomes. While incretin-based therapies have transformed metabolic care, data on tirzepatide-a dual GIP/GLP-1 receptor agonist-in solid organ transplantation (SOT) a...

Schmidt PHS, de Souza VSN, Machado LG, Rodrigues JVA, da Cruz JVR, de Souza LSN et al.

To evaluate the effects of tirzepatide on physical function in adults with overweight or obesity.We searched PubMed, Embase, and the Cochrane Library up to July 20, 2025 for randomized controlled trials (RCTs) comparing once-weekly tirzepatide 10 or 15 mg with placebo and reporting validat...

Makkena HB

Background The rapid adoption of incretin-based therapies for obesity has raised questions regarding their comparative safety profiles. While the gynecological safety of glucagon-like peptide-1 (GLP-1) receptor agonists is documented, the potential risks associated with dual glucose-dependent ins...

Belančić A, Antza C, Poutachidis A, Palaska S, Gkrinia EMM, Faour AK et al.

Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta-analysis (NMA) systemat...

Kahles F, Birkenfeld AL, Marx N

The incretin hormone glucagon-like peptide-1 (GLP-1) exerts potent effects on glucose metabolism, prompting the development of therapeutic strategies that enhance activity of the GLP-1 receptor (GLP-1R) pathway. Inhibitors of dipeptidyl peptidase 4 (DPP-4) prolong the half-life of endogenous GLP-...

Patil S, Jha N, Jha MK

Substance use disorders (SUDs) are widely prevalent and associated with high morbidity and mortality. Current treatments have limited efficacy and there are no United States Food and Drug Administration (FDA)-approved treatments for several SUDs (such as methamphetamine, cocaine, and cannabis use...

Valente V, Beer BN, Savarese G

Heart failure with preserved ejection fraction (HFpEF) represents approximately half of all heart failure cases and poses a growing global health challenge driven by an ageing population and an increasing comorbidity burden. Once regarded as a condition without effective, evidence-based therapy, ...

Sekhon S, Kahlon I, Latson W

Tirzepatide has been approved for the management of obesity, obstructive sleep apnea, and type 2 diabetes mellitus; while gastrointestinal side effects are commonly seen, ischemic colitis has been only rarely described. We present the case of a 32-year-old woman with no prior medical history...

Belcourt J, Sapowadia A, White CM

With the shortage of innovator semaglutide or tirzepatide products resolved, compounding pharmacies can only legally sell unique products. Unique products could have a different route of administration or dosing, or could include additional pharmaceutical ingredients.To identify and characterize ...

Menkü Özdemir FD, Uzun H

Skin redundancy after massive weight loss often requires body contouring procedures such as abdominoplasty and mastopexy. Bariatric patients may face higher complication risks due to nutritional deficiencies. However, with proper management, including stable body weight and adequate nutritional s...

De Oliveira-Gomes D, de Majo AM, Ardila-Delgado A, Inglis SS, Mandras SA, Loro-Ferrer JF et al.

This review examines the mechanistic pathways linking obesity and cardiovascular disease, with particular emphasis on recent advancements in pharmacologic therapies. It evaluates the cardiovascular effects of novel anti-obesity medications and their integration into current treatment paradigms. A...

Tam S, Persaud V, Wertheimer A

Telehealth has become a mainstream healthcare delivery methods driven by advances in health technology, evolving patient preferences, and the need for more accessible and affordable care. While traditional pharmacy models remain effective, they face numerous challenges, including medication acces...

Murray M, Schifano F, Chiappini S, Corkery JM, Guirguis A

Boye KS, Cutts KN, Coyne KS, Matza LS

Over the past 2 decades, treatment for type 2 diabetes (T2D) has evolved with the introduction of medications that offer greater simplicity. The Simplicity of Diabetes Treatment Questionnaire (Sim-Q™) was developed to assess the simplicity or complexity of treatment for T2D. This...